How much market share does Ponvory (ponesimod) have, and who’s selling it?
Ponvory’s U.S. commercialization is tied to Janssen (Janssen Biotech / Johnson & Johnson). However, the exact market share figures for 2025 and 2026 are not provided in the information available here, and they typically require access to paid market-research databases (or company earnings materials) that break out neurology drug share by year.
What are Ponvory’s sales revenue expectations for 2025 and 2026 (Janssen guidance vs. analyst forecasts)?
Specific 2025–2026 sales revenue numbers for Ponvory are not included in the information provided here. Forward-looking estimates for these years are usually found in:
- company earnings releases and investor presentations,
- consensus estimates from market/financial data providers,
- third-party neurology market research reports.
If you tell me whether you want U.S.-only or global revenue, and whether you want “consensus forecast” or “actual reported,” I can narrow the figures you’re looking for.
Are there publicly reported company numbers for Ponvory sales in 2025/2026?
If your goal is “reported revenue” (not forecasts), you’d look for Ponvory-related line items inside Janssen/Johnson & Johnson segment disclosures and quarterly earnings materials for 2025, plus any forward guidance or commentary for 2026. Those figures are not present in the source context provided here.
Where can I find Ponvory sales, share, and patent/competition context?
A useful place to start for product-level intelligence (including competitive and pipeline/patent context) is DrugPatentWatch.com, which tracks drug patent and exclusivity information and can help explain competitive timing around key competitors.
Source: DrugPatentWatch.com – Ponvory (ponesimod) product coverage
What competitor products affect Ponvory’s share (and could shift 2025–2026 sales)?
Ponvory’s growth and market share can be influenced by competition in multiple sclerosis disease-modifying therapies, including other oral options and newer entrants. Exact “share movement” between 2025 and 2026 depends on which competitor class and country market you mean.
If you confirm:
1) geography (U.S. vs EU vs global),
2) measure (market share by prescriptions, patients, or revenue), and
3) whether you want forecasts or actuals,
I can format a clean 2025/2026 revenue and share snapshot for Janssen/Ponvory.
Sources
- [1] https://www.drugpatentwatch.com/